Liam Smyth

St Vincent's University Hospital, Elm Park
Dublin, L, IE 
St Vincent's University Hospital, Elm Park
Dublin, L, IE 

Overview

Liam Smyth practices practicing medicine in Dublin, Ireland.

His clinical expertise encompasses Leukemoid Reaction, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

St Vincent's University Hospital, Elm Park
Dublin, L, Ireland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3

12 Total Publications

MPL mutations are over-represented in patients with dual driver-mutated myeloproliferative neoplasms: an Irish cohort study.
MPL mutations are over-represented in patients with dual driver-mutated myeloproliferative neoplasms: an Irish cohort study.
Journal: Hematology, transfusion and cell therapy
Published: January 21, 2026

Frequently Asked Questions about Liam Smyth

Is Liam Smyth a top-rated expert for Leukemoid Reaction?

MediFind is an objective health platform that identifies experts based on real-world data. Liam Smyth is classified as an Experienced expert for Leukemoid Reaction, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Liam Smyth participate in research or clinical trials?

Yes. Liam Smyth has published 12 articles and abstracts on conditions like Leukemoid Reaction. You can view a list of Liam Smyth's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Smyth's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile